Medications for unhealthy alcohol use: across the spectrum
- PMID: 23580015
- PMCID: PMC3860540
Medications for unhealthy alcohol use: across the spectrum
Abstract
The prevalence of unidentified or untreated unhealthy alcohol use remains high. With the advent of pharmacotherapy and models of counseling appropriate for use in primary care settings as well as in specialty care, clinicians have new tools to manage the range of alcohol problems across the spectrum of health care settings. By extending treatment to primary care, many people who do not currently receive specialty care may have increased access to treatment. In addition, primary care providers, by virtue of their ongoing relationship with patients, may be able to provide continuing treatment over time. Extending the spectrum of care to hazardous drinkers who may not be alcohol dependent could result in earlier intervention and reduce the consequences of excessive drinking.
Similar articles
-
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Biochem Pharmacol. 2008 Jan 1;75(1):34-56. doi: 10.1016/j.bcp.2007.08.005. Epub 2007 Aug 9. Biochem Pharmacol. 2008. PMID: 17880925 Free PMC article. Review.
-
The state of pharmacotherapy for the treatment of alcohol dependence.J Subst Abuse Treat. 2009 Jan;36(1):S15-23; quiz S24-5. J Subst Abuse Treat. 2009. PMID: 19062347 Review.
-
Recent advances in the pharmacotherapy of alcoholism.Curr Psychiatry Rep. 2004 Oct;6(5):332-8. doi: 10.1007/s11920-004-0019-7. Curr Psychiatry Rep. 2004. PMID: 15355755 Review.
-
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.Alcohol Clin Exp Res. 2010 Dec;34(12):2022-34. doi: 10.1111/j.1530-0277.2010.01290.x. Alcohol Clin Exp Res. 2010. PMID: 20659066
-
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.Addict Sci Clin Pract. 2016 Sep 15;11(1):15. doi: 10.1186/s13722-016-0063-8. Addict Sci Clin Pract. 2016. PMID: 27633982 Free PMC article.
Cited by
-
Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population.Lancet Psychiatry. 2017 Jun;4(6):469-476. doi: 10.1016/S2215-0366(17)30130-X. Epub 2017 Apr 26. Lancet Psychiatry. 2017. PMID: 28456501 Free PMC article.
-
Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?Drugs. 2021 May;81(7):739-748. doi: 10.1007/s40265-021-01509-x. Epub 2021 Apr 8. Drugs. 2021. PMID: 33830479 Review.
-
Differential Influence of Pueraria lobata Root Extract and Its Main Isoflavones on Ghrelin Levels in Alcohol-Treated Rats.Pharmaceuticals (Basel). 2021 Dec 24;15(1):25. doi: 10.3390/ph15010025. Pharmaceuticals (Basel). 2021. PMID: 35056082 Free PMC article.
-
A novel human laboratory model for screening medications for alcohol use disorder.Trials. 2020 Nov 23;21(1):947. doi: 10.1186/s13063-020-04842-w. Trials. 2020. PMID: 33225963 Free PMC article. Clinical Trial.
-
Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy.Pharmacol Ther. 2022 Dec;240:108299. doi: 10.1016/j.pharmthera.2022.108299. Epub 2022 Oct 30. Pharmacol Ther. 2022. PMID: 36323379 Free PMC article. Review.
References
-
- Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922. - PubMed
-
- Anton RF, Drobes DJ, Voronin K, et al. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: Temporal effects of drinking. Psychopharmacology (Berlin) 2004;173(12):32–40. - PubMed
-
- Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 2008a;28(1):5–12. - PubMed
-
- Anton RF, Myrick H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms. Journal of Clinical Psychopharmacology. 2009;29(4):334–342. - PubMed
-
- Anton RF, Oroszi G, O’Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. Archives of General Psychiatry. 2008b;65(2):135–144. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical